CA2457245C - Transdermal therapeutic system (tts) containing the active substance fentanyl - Google Patents
Transdermal therapeutic system (tts) containing the active substance fentanyl Download PDFInfo
- Publication number
- CA2457245C CA2457245C CA2457245A CA2457245A CA2457245C CA 2457245 C CA2457245 C CA 2457245C CA 2457245 A CA2457245 A CA 2457245A CA 2457245 A CA2457245 A CA 2457245A CA 2457245 C CA2457245 C CA 2457245C
- Authority
- CA
- Canada
- Prior art keywords
- active substance
- tts
- layer
- fentanyl
- microreservoirs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
The invention relates to transdermal therapeutic systems with fentanyl or an analogous fentanyl derivative as active ingredient. In order to prevent inadvertent overdosage by uncontrolled release of active ingredient as a result of damage, the active ingerdient is contained in fluid-filled micro-reservoirs in the layer containing the active ingredient. The layer containing the active ingredient can optionally be provided with a membrane.
Description
Transdermal therapeutic system (TTS) containing the active substance fentanyl The present invention relates to a transdermal therapeutic system (TTS) containing the active substance fentanyl.
Fentanyl and fentanyl analog derivatives such as sulfentanyl, carfentanyl, lofentanyl, and alfentanyl are extremely active analgesics. Their low dosage and their physicochemical properties such as, for example, the n-octanollwater partition coefficient, the melting point, and the molecular weight make it possible to supply the substances transdermally in an effective amount, and their pharmacokinetic properties such as the rapid metabolization and the relatively ~s narrow therapeutic index make their transdermal supply desirable.
Indeed, for a number of years a fentanyl TTS has been on the market. This system is of the type known as a reservoir system. A reservoir system is a TTS
which contains the active substance in a liquid or gel formulation in a pouch 2o formed from an impermeable film and a membrane which is permeable for the active substance. The impermeable film acts as a backing layer, in order to prevent the liquid or gel formulation of the active substance emerging on the side of the pouch facing away from the skin. The membrane serves to regulate the rate of active substance release from the skin-facing side of the pouch. On this side, 25 the membrane additionally possesses an adhesive layer for attaching the overall TTS to the skin.
In this specific case (Durogesic~ TTS), fentanyl is in solution in a mixture of ethanol and water. Further details of this system can be found in US patent 30 4,588,580 or DE 35 26 339, both of which contain a detailed description.
However, reservoir systems have a major disadvantage, namely that in the event of a leak (e.g., a simple mechanically induced damage, a cut or tear, splitting of the weld seam, etc.) in the pouch containing the active substance formulation, the active substance may come into contact with the skin over a large area and, as a consequence of this contact, may be absorbed in excessive doses. Especially in the case of fentanyl and the fentanyl analog derivatives, this is potentially fatal, since overdose leads very rapidly to respiratory depression and hence fatal incidents. A number of such fatal or near-fatal incidents have been described in Clinical Pharmacokinet. 2000, 38 (1), 59-89.
It is an object of the present invention to provide a transdermal therapeutic system comprising the active substance fentanyl and/or fentanyl analog derivatives which offers the user increased security against inadvertent overdose.
This object is achieved by means of a transdermal therapeutic system which comprises a backing layer, an active substance layer, and a protective layer, to be removed before use. The active substance layer is composed of a polymer into which a multiplicity of liquid microreservoirs have been incorporated. These microreservoirs contain the active substance.
As has been found, despite the fact that the active substance is contained in a liquid formulation within the active substance layer, said layer is absolutely (eakproof even when damaged mechanically (cuts, tears, abrasion, etc.). The user is therefore at no risk in respect of uncontrolled release or inadvertent overdose as 2s a consequence of unintended or deliberate damage to the active substance layer.
From a purely external standpoint, there is no difference between this kind of transdermal therapeutic system and the second major TTS type, a matrix system.
With the TTS of the invention, the internal structure of the active substance layer 3o can be perceived only under the microscope. The liquid microreservoirs are embedded in the form of small droplets in the (preferably self-adhesive) active substance layer. (These droplets adopt an approximately spherical form.) A
Fentanyl and fentanyl analog derivatives such as sulfentanyl, carfentanyl, lofentanyl, and alfentanyl are extremely active analgesics. Their low dosage and their physicochemical properties such as, for example, the n-octanollwater partition coefficient, the melting point, and the molecular weight make it possible to supply the substances transdermally in an effective amount, and their pharmacokinetic properties such as the rapid metabolization and the relatively ~s narrow therapeutic index make their transdermal supply desirable.
Indeed, for a number of years a fentanyl TTS has been on the market. This system is of the type known as a reservoir system. A reservoir system is a TTS
which contains the active substance in a liquid or gel formulation in a pouch 2o formed from an impermeable film and a membrane which is permeable for the active substance. The impermeable film acts as a backing layer, in order to prevent the liquid or gel formulation of the active substance emerging on the side of the pouch facing away from the skin. The membrane serves to regulate the rate of active substance release from the skin-facing side of the pouch. On this side, 25 the membrane additionally possesses an adhesive layer for attaching the overall TTS to the skin.
In this specific case (Durogesic~ TTS), fentanyl is in solution in a mixture of ethanol and water. Further details of this system can be found in US patent 30 4,588,580 or DE 35 26 339, both of which contain a detailed description.
However, reservoir systems have a major disadvantage, namely that in the event of a leak (e.g., a simple mechanically induced damage, a cut or tear, splitting of the weld seam, etc.) in the pouch containing the active substance formulation, the active substance may come into contact with the skin over a large area and, as a consequence of this contact, may be absorbed in excessive doses. Especially in the case of fentanyl and the fentanyl analog derivatives, this is potentially fatal, since overdose leads very rapidly to respiratory depression and hence fatal incidents. A number of such fatal or near-fatal incidents have been described in Clinical Pharmacokinet. 2000, 38 (1), 59-89.
It is an object of the present invention to provide a transdermal therapeutic system comprising the active substance fentanyl and/or fentanyl analog derivatives which offers the user increased security against inadvertent overdose.
This object is achieved by means of a transdermal therapeutic system which comprises a backing layer, an active substance layer, and a protective layer, to be removed before use. The active substance layer is composed of a polymer into which a multiplicity of liquid microreservoirs have been incorporated. These microreservoirs contain the active substance.
As has been found, despite the fact that the active substance is contained in a liquid formulation within the active substance layer, said layer is absolutely (eakproof even when damaged mechanically (cuts, tears, abrasion, etc.). The user is therefore at no risk in respect of uncontrolled release or inadvertent overdose as 2s a consequence of unintended or deliberate damage to the active substance layer.
From a purely external standpoint, there is no difference between this kind of transdermal therapeutic system and the second major TTS type, a matrix system.
With the TTS of the invention, the internal structure of the active substance layer 3o can be perceived only under the microscope. The liquid microreservoirs are embedded in the form of small droplets in the (preferably self-adhesive) active substance layer. (These droplets adopt an approximately spherical form.) A
transdermal therapeutic system with an active substance layer constructed in this way will be referred to hereinbelow as a "microreservoir system".
These liquid microreservoirs have an average diameter of about 5 - 50,urn. In any s case, however, they must be smaller than the thickness of the active substance layer, since othervvise the active substance liquid could escape. The size of the microresenroirs can be influenced by the choice of suitable liquids and by regulating certain parameters during the preparation process.
1o Like a matrix system, the microreservoir system of the invention is thus composed at its most simple of three layers: a backing layer, impermeable to the active substance; the self-adhesive active substance layer, with the microreservoirs;
and a protective layer, to be removed before use. A system of this kind is illustrated in fig. 1.
Even in the case of a microreservoir system, however, it may be necessary in certain circumstances to limit the amount of active substance to be delivered by the transdermal therapeutic system over a certain period of time. This can be achieved by means of a membrane which adjoins the active substance layer on 2o the skin side, and which for attachment to the skin may additionally be provided with an adhesive layer. During the preparation process, this skin-side adhesive layer may be provided with a limited amount of active substance which, following application of such a microreservoir system, is delivered to the skin and hence into the organism in a way which cannot be controlled by the membrane. The purpose of this measure is to shorten the time until a therapeutic plasma level is reached (known as the "lag time"). A microreservoir system with membrane is depicted in fig. 2.
Suitable active substances include fentanyl and/or fentanyl analog derivatives, so preferably sulfentanyl, carfentanyl, lofentanyl, and alfentanyl. The active substance is preferably in the form of the free base; alternatively, it may be used in the form of a pharmaceutically acceptable salt or as a mixture of the free base with a pharmaceutically acceptable salt of said base. Examples of suitable salts include the hydrochlorides, hydrobromides, sulfates, hydrogen sulfates, citrates, and tartrates.
s As already mentioned, fentanyl and the fentanyl analog derivatives possess a narrow therapeutic index. This means that the active substance release rate of a transdermal therapeutic system containing fentanyl or a fentanyl analog must be controlled with very great precision.
It has been found that the polymer or polymer blend which provides the active substance layer with its internal cohesion, and in which the microreservoirs are embedded, must meet certain requirements regarding dissolution capacity for the active substance and miscibility with the liquids which form the microreservoirs.
Accordingly, the dissolution capacity for the active substance should be low, so ~5 that the majority of the active substance is located within the microreservoirs and not in the polymer itself. Further, the polymer should be substantially immiscible with the liquids which form the microreservoirs. These measures ensure that, first, the formation of microreservoirs is actually possible and that, secondly, the dissolution capacity of the polymer phase for the active substance is not too high.
Polymers which have been found to be suitable include hydrophobic polymers, which preferably possess pressure sensitive adhesion. These include polyisobutylenes and silicones (polysiloxanes). Amine-resistant polysiloxanes have proven particularly suitable. In solubility studies it has been found that the solubility of the active substance in such polymers is low. For example, fentanyl in base form has a solubility in such polymers of less than 0.5% by weight.
Amine-resistant polymers of this kind are produced, for example, by Dow Corning and are sold under the trade name BIO-PSA. The tackiness of these polymers 3o ranges from nontacky via moderately strongly to strongly tacky, the appropriate tack also being adjustable by blending of the individual types and/or by adding low molecular mass substances such as silicone oil, for example.
These liquid microreservoirs have an average diameter of about 5 - 50,urn. In any s case, however, they must be smaller than the thickness of the active substance layer, since othervvise the active substance liquid could escape. The size of the microresenroirs can be influenced by the choice of suitable liquids and by regulating certain parameters during the preparation process.
1o Like a matrix system, the microreservoir system of the invention is thus composed at its most simple of three layers: a backing layer, impermeable to the active substance; the self-adhesive active substance layer, with the microreservoirs;
and a protective layer, to be removed before use. A system of this kind is illustrated in fig. 1.
Even in the case of a microreservoir system, however, it may be necessary in certain circumstances to limit the amount of active substance to be delivered by the transdermal therapeutic system over a certain period of time. This can be achieved by means of a membrane which adjoins the active substance layer on 2o the skin side, and which for attachment to the skin may additionally be provided with an adhesive layer. During the preparation process, this skin-side adhesive layer may be provided with a limited amount of active substance which, following application of such a microreservoir system, is delivered to the skin and hence into the organism in a way which cannot be controlled by the membrane. The purpose of this measure is to shorten the time until a therapeutic plasma level is reached (known as the "lag time"). A microreservoir system with membrane is depicted in fig. 2.
Suitable active substances include fentanyl and/or fentanyl analog derivatives, so preferably sulfentanyl, carfentanyl, lofentanyl, and alfentanyl. The active substance is preferably in the form of the free base; alternatively, it may be used in the form of a pharmaceutically acceptable salt or as a mixture of the free base with a pharmaceutically acceptable salt of said base. Examples of suitable salts include the hydrochlorides, hydrobromides, sulfates, hydrogen sulfates, citrates, and tartrates.
s As already mentioned, fentanyl and the fentanyl analog derivatives possess a narrow therapeutic index. This means that the active substance release rate of a transdermal therapeutic system containing fentanyl or a fentanyl analog must be controlled with very great precision.
It has been found that the polymer or polymer blend which provides the active substance layer with its internal cohesion, and in which the microreservoirs are embedded, must meet certain requirements regarding dissolution capacity for the active substance and miscibility with the liquids which form the microreservoirs.
Accordingly, the dissolution capacity for the active substance should be low, so ~5 that the majority of the active substance is located within the microreservoirs and not in the polymer itself. Further, the polymer should be substantially immiscible with the liquids which form the microreservoirs. These measures ensure that, first, the formation of microreservoirs is actually possible and that, secondly, the dissolution capacity of the polymer phase for the active substance is not too high.
Polymers which have been found to be suitable include hydrophobic polymers, which preferably possess pressure sensitive adhesion. These include polyisobutylenes and silicones (polysiloxanes). Amine-resistant polysiloxanes have proven particularly suitable. In solubility studies it has been found that the solubility of the active substance in such polymers is low. For example, fentanyl in base form has a solubility in such polymers of less than 0.5% by weight.
Amine-resistant polymers of this kind are produced, for example, by Dow Corning and are sold under the trade name BIO-PSA. The tackiness of these polymers 3o ranges from nontacky via moderately strongly to strongly tacky, the appropriate tack also being adjustable by blending of the individual types and/or by adding low molecular mass substances such as silicone oil, for example.
The advantage of the amine-resistant polysiloxanes is that they possess no free siloxanol groups and therefore do not tend to undergo condensation reactions in the presence of basic active substances or salts of basic active substances, with s adverse consequences for the bond strength. Moreover, the interaction with the polar groups of the active substance molecules is lessened.
Solvents which can be used for the polymer include low-polarity and/or hydrophobic solvents. Amine-resistant polysiloxanes are offered in a variety of solvent systems. The most suitable solvents for the production of transdermal therapeutic systems in the context of this invention are n-heptane and comparable hydrocarbons, since the liquids envisaged for the microreservoirs are of only poor miscibility with this solvent.
15 As a result, during preparation, the solution of the active substance in the micro-reservoir liquid can be dispersed in the solution of the polysiloxane and thus the size of the microreservoirs in the composition to be coated can be set at this stage by virtue of the stirring conditions. For the purposes of the present description, a dispersion is a system which is composed of a continuous phase (which is made 2o of polymer) and of the microreservoirs, which are not mutually contiguous (and which are made up of the liquid droplets).
The liquid, which constitutes an important ingredient of the microreservoirs, should be at least partly miscible both with water and with organic solvents. It may 25 therefore also be referred to as ambiphilic.
Moreover, the liquid should possess a good solvency for the active substance, in order to accommodate the required amount of active substance in customary TTS
active substance layer thicknesses of about 30 to 300,um, correspond to a coating 3o weight of 30 - 300 g/m2.
Dipropylene glycol, diethylene glycol monoethyl ether, diethylene glycol diethyl ether, diethylene glycol monomethyl ether, diethylene glycol dimethyl ether, 1,3-butanediol, 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane, 2-pyrrolidone, and N-methylpyrrolidone have proven particularly suitable. Instead of the substances s alone it is of course also possible to take blends thereof.
The saturation solubilities of fentanyl, measured in different liquids suitable for use as tile microreservoirs, are shown in table 1.
Table 1: Saturation solubility of fentanyl in different liquids Microreservoir liquid Solubility [%
wlw]
1,3-Butanediol 10 Dipropylene glycol 18 Transcutol* 25 Diethylene glycol diethyl26 ether N-Methylpyrrolidone 26 * Diethylene glycol monoethyl ether Accordingly, the solubility of fentanyl in base form is higher by a factor of about ~s 20 - 50 in the liquids envisaged for the microreservoirs than in the polysiloxane polymer. This is more than sufficient to accommodate the required amount of active substance within a microreservoir matrix not exceeding 200,um in thickness, in a system with an acceptable areal size.
2o The high solubility of fentanyl in the liquids envisaged for the microreservoirs coupled with its low solubility in the silicone polymer has the effect, moreover, that by far the predominant portion of the fentanyl is actually located within the microreservoirs and not in solution in the polymer phase.
Prior to application of a TTS of the invention, preferably more than 50% of the total active substance present in the TTS is situated within the microreservoirs, since otherwise, because of the poor solubility in the polymer, the active substance layers are too thick and the service properties poor for the finished system.
The total concentration of the active substance in the active substance layer is only between 2 and 5% by weight, which then also corresponds approximately to ~o the saturation concentration of the active substance in the polymer. This means that, despite the low concentration, the thermodynamic activity of the active substance is at a maximum, i.e., at or just below 1.
The fraction of the microreservoirs in the active substance layer may amount to up ~s to 40% by weight, although it is advantageous not to exceed 30% by weight.
It has proven advantageous to add to these liquids a substance which raises their viscosity. Such substances may comprise polymers which are capable of forming a gel with the liquid. Mention may be made by way of example of ethylcellulose 2o and hydroxypropylcellulose, which are also used in the examples. This measure facilitates the dispersibility of the liquid in the solution of the polymer and may also result in smaller microreservoir diameters.
For microreservoir systems of the invention which are provided with a membrane, 25 either microporous membranes or what are known as distribution membranes may be used. Microporous membranes are films provided with microscopic pores or channels. Here, the transport of active substance is substantially through these pores or channels, which must therefore be filled with a medium which is diffusible for the active substance (e.g., a liquid, gas, gel or other material). The number, the 3o internal surface area, and the size of the pores, and the physicochemical properties of the pore or channel filling substantially determine the release of active substance (permeation rate).
Distribution membranes do not possess any pores; in other words, the active substance must diffuse through the membrane material itself. When membranes of this kind are used, it is the thickness of the membrane, and the solubility and diffusion coefficient of the active substance in the membrane material, which determine the release of active substance. Distribution membranes which have proven particularly highly suitable are those based on copolymers of ethylene and vinyC acetate (EVA). Membranes of this kind are available in a variety of thicknesses and with different compositions. Customary thicknesses range ~o between 20 and 150 Nm, and the vinyl acetate (VA) content between 2 and 25%
by weight.
Since the VA content has an effect on the solubility and the diffusion coefficient of the active substances in the EVA polymers, it is a further important membrane ~ s characterization parameter where membranes made of this material are being used. In the examples, a membrane 50,um thick with a VA content of 9% by weight has been used. The permeation rates achieved using this membrane can be raised through the use of thinner membranes or membranes having a higher VA content. Naturally, the use of thicker membranes and the reduction of the VA
2o content has the opposite effect.
Especially when systems without membrane control are used, the active substance intake, i.e., the amount of active substance delivered by the TTS
that is actually absorbed via the skin into the blood circulation is also dependent on the 2s permeability of the skin. The outer skin layer in particular, the stratum corneum, forms the principal barrier against penetrative active substances. This barrier function can be lowered through the use of what are called enhancers, thereby increasing the active substance intake. Enhancers are known to the skilled worker, for example, from the publication "Skin penetration enhancers cited in the 3o technical literature" by David W. Osborne and Jill J. Henke, ViroTex Corporation, which can be called up on the Internet at http:/Iwww.pharmtech.com/technical/osborne/osborne.htm and which in order to avoid repetition is intended in its entirety to form part of the disclosure content of this specification.
For the transdermal therapeutic systems of the present invention it is possible with s particular advantage to use fatty acid, fatty acid ester, fatty alcohol or glycerol ester enhancers, especially when fentanyl is the active substance being used.
For fhe preparation of the active substance layer, the active substance is dissolved in the liquid which forms the microreservoirs, and this solution is dispersed in the solution of the polymer. The resulting dispersion is then used to coat an appropriate substrate - normally a polyester film with an abhesive coating - and the solvent of the polymer is removed by drying. The drying conditions should be chosen such that only a small proportion if any of the microreservoir solvent is removed. It has been found that the liquid and the solvent are preferably selected such that the solvent possesses a boiling temperature which is at least about 30°, with particular preference at least 50°, below the boiling temperature of the liquid.
The dry matrix film is then laminated to the backing layer of the system -usually 2o an active substance impermeable film with a thickness of about 15 - 30,um -and the individual transdermal therapeutic systems are then punched from the overall laminate obtained.
The production of corresponding microreservoir systems comprising membranes 2s is somewhat more complicated, but in terms of the coating and laminating process is no different from the production of known systems with the same layer sequence. In the examples, the production of microreservoir systems with and without membranes is described in detail.
3o Using three transdermal therapeutic systems provided by this invention, i.e.
microreservoir systems with and without membranes, permeation studies were conducted using human epidermis and Franz diffusion cells, which are known to the skilled worker. The composition and the results are summarized in tables 2 to 5, with the preparation process described in detail in the examples.
Table 2: Composition of the microreservoir systems without membranes Composition [% w/w]
Formulation A B C
Ingredients Fentanyl base 2.0 3.6 5.0 BIO-PSA 4301 * 80.0 80.0 80 1,3-Butanediol 17.46 Dipropylene glycol 16.07 Transcutol** 14.4 Hydroxypropyl-cellulose0.54 0.33 Ethylcellulose 100NF 0,6 Coating weight [glm']130 85 65 Matrix thickness, 140 95 75 approx. [arm]
* Amine-resistant silicone adhesive with high bond strength ** Diethylene glycol monoethyl ether Table 3: Results of the permeation study with formulations A, B and C
Cumulative Average permeated release fentanyl rate base [,ug/cm'J*
Formulation4 h 8 h 24 h 48 h 72 h [,ug/cm'*h]
D [sic] 1.2 9.5 84.4 194.0 275.0 3.82 E [sic] 1.12 8.87 75.80 191.00 283.00 3.93 F [sic] 16.20 45.20 131.00 212.00 262.00 3.64 * Averages of n = 3 Table 4: Composition of the systems with control membrane Composition [% w/w]
Formulation D E F
Ingredients Reservoir layer Fentanyl base 2.0 3.6 5.0 B I O-PSA 4301 * 80.0 80.0 80 1,3-Butanediol 17.46 Dipropylene glycol 16.07 Transcutol** 14.4 Hydroxypropyl-cellulose0.54 0.33 Ethylcellulose 100NF 0.6 Coating weight [glm']130 85 65 Control membrane EVA membrane 50,um, 9% VA
Skin contact layer BIO-PSA 4301 * 100 100 100 Coating weight [g/m']35 35 35 * Amine-resistant silicone adhesive with high bond strength ** Diethylene glycol monoethyl ether s Table 5: Results of the permeation study with formulations D, E and F
Cumulative Average permeated release fentanyl rate base [/rg/cm']*
Formulation4 h 8 h 24 h 48 h 72 h [~.~g/cm'*h]
D 1.4 4.9 26.2 64.0 99.8 1.39 E 2.7 8.1 37.0 85.0 129.0 1.79 F 0.8 4.7 45.3 114.0 166.0 2.31 * Averages of n = 3 Comparing the permeation results of the microreservoir systems with and without a membrane it can be seen that the amount of active substance permeated after 72 hours is much lower in the case of the membrane systems, despite the active substance layers having the same composition. This can be attributed to the controlling effect of the membrane, which limits the delivery of active substance to a maximum irrespective of the particular nature of the skin.
The graphs (figs. 3 and 4) also reveal that, as the result of the use of a membrane, the permeation profile is more linear and hence also the active substance intake in vivo is more uniform over the period of use. It is particularly evident in the case of formulation C, which shows the highest permeation rate.
The TTS present on the market (Durogesic~) is available in 4 strengths with average delivery rates of 25, 50, 75, and 100,um/hour. With these figures and the results of the permeation studies, it is possible to calculate the surface areas of the systems with ease. The results are summarized in table 6.
Table 6: Cahulated system surface areas of formulations A-F
Calculated Delivery areal rate sizes [cm ]
A B C D E F
,um/ 6.5 6.4 6.9 18.0 14.0 11.8 h 50 Nml 13.0 12.8 13.8 36.0 28.0 23.6 h 75 Nml 19.5 19.2 20.7 54.0 42.0 35.4 h 100 Nml 26.0 25.6 27.6 72.0 56.0 47.2 h 2o The calculated surface areas all lie within an acceptable range. The size of the microreservoir systems with membrane can be made smaller still through the use of thinner membranes or membranes with a higher VA content, although in that case the control of the delivery of active substance by the membrane will be less effective.
Microreservoir systems as provided by this invention therefore show very good permeation rates, which without a control membrane lead to TTS which are small in terms of area and are pleasant to wear. At the same time, there is absolutely no possibility of any risk to the patient from excessive active substance intake due to leakage.
s In the case of microreservoir systems with membranes, the membrane control which limits the delivery of active substance results in patch sizes which are larger but still acceptable.
All in all, therefore, microreservoir systems for fentanyl and the fentanyl analog 1 o derivatives constitute a decisive step forward in terms of wear comfort and patient safety from the known prior art.
The preparation examples which follow describe the preparation of microreservoir systems with and without membranes.
Example 1: Microreservoir system with 1,3-butanediol as liquid, formulation A
1 g of fentanyl base is dissolved in 9 g of 1,3-butanediol, thickened with 3%
hydroxypropylcellulose. To this solution there are added 54.8 g of a 73%
strength 2o solution of an amine-resistant silicone adhesive in n-heptane (BIO-PSA
4301, Dow Corning) and the active substance solution is dispersed in the solution of the silicone adhesive by rapid stirring. The dispersion is then knife-coated onto an abhesively coated film, the protective layer to be removed later prior to use (Scotchpak 1022, 3M), in a thickness which following removal of the n-heptane by drying at 30°C for 15 minutes results in a coating weight of 135 g/m2.
The dry film is then laminated with the active substance impermeable backing layer (Scotchpak 1220, 3M) and the finished transdermal therapeutic system is punched from the overall laminate which results.
Example 2: Microreservoir system with dipropylene glycol as liquid, formulation B
1 g of fentanyl base is dissolved in 4.6 g of dipropylene glycol, thickened with 2%
hydroxypropylcellulose. To this solution there are added 30.5 g of a 73%
strength s solution of an amine-resistant silicone adhesive in n-heptane (B!O-PSA 4301, Dow Corning) and the active substance solution is dispersed in the solution of the silicone adhesive by rapid stirring. The dispersion is then knife-coated onto an abhcsively coated film, the protective layer to be removed later prior to use (Scotchpak 1022, 3M), in a thickness which following removal of the n-heptane by drying at 30°C for 15 minutes results in a coating weight of 85 g/m2.
The dry film is then laminated with the active substance impermeable backing layer (Scotchpak 1220, 3M) and the finished transdermal therapeutic system is punched from the overall laminate which results.
~s Example 3: Microreservoir system with Transcutol as liquid, formulation C
1 g of fentanyl base is dissolved in 3 g of Transcutol, thickened with 4%
ethylcellulose. To this solution there are added 22 g of a 73% strength solution of an amine-resistant silicone adhesive in n-heptane (BIO-PSA 4301, Dow Corning) 2o and the active substance solution is dispersed in the solution of the silicone adhesive by rapid stirring. The dispersion is then knife-coated onto an abhesively coated film, the protective layer to be removed later prior to use (Scotchpak 1022, 3M), in a thickness which following removal of the n-heptane by drying at 30°C for 15 minutes results in a coating weight of 65 g/m2. The dry film is then laminated 2s with the active substance impermeable backing layer (Scotchpak 1220, 3M) and the finished transdermal therapeutic system is punched from the overall laminate which results.
Examples 4 - 6: Microreservoir systems with membranes, formulations D, E, and F
The solution of an amine-resistant silicone adhesive (BIO-PSA 4301, Dow s Corning) is knife-coated to an abhesively coated film (Scotchpak 1022, 3M) in a thickness such that removal of the n-heptane by drying at 30°C for 15 minutes gives a coating weight of 20 g/m2. The dried film is laminated with a membrane (EVA, 50Nm, 9% VA, 3M).
The protective layer is removed from the laminates from examples 1 - 3 and the laminate consisting of active substance layer and backing layer is laminated onto this membrane. The resulting overall laminate (formulations D, E and F) are then punched to give the finished transdermal therapeutic systems.
15 In the figures, the elements shown are as follows:
1 = backing layer 2 = active substance layer with microreservoirs 3 = microreservoir 4 = control membrane 20 5 = skin contact layer 6 = removable protective layer
Solvents which can be used for the polymer include low-polarity and/or hydrophobic solvents. Amine-resistant polysiloxanes are offered in a variety of solvent systems. The most suitable solvents for the production of transdermal therapeutic systems in the context of this invention are n-heptane and comparable hydrocarbons, since the liquids envisaged for the microreservoirs are of only poor miscibility with this solvent.
15 As a result, during preparation, the solution of the active substance in the micro-reservoir liquid can be dispersed in the solution of the polysiloxane and thus the size of the microreservoirs in the composition to be coated can be set at this stage by virtue of the stirring conditions. For the purposes of the present description, a dispersion is a system which is composed of a continuous phase (which is made 2o of polymer) and of the microreservoirs, which are not mutually contiguous (and which are made up of the liquid droplets).
The liquid, which constitutes an important ingredient of the microreservoirs, should be at least partly miscible both with water and with organic solvents. It may 25 therefore also be referred to as ambiphilic.
Moreover, the liquid should possess a good solvency for the active substance, in order to accommodate the required amount of active substance in customary TTS
active substance layer thicknesses of about 30 to 300,um, correspond to a coating 3o weight of 30 - 300 g/m2.
Dipropylene glycol, diethylene glycol monoethyl ether, diethylene glycol diethyl ether, diethylene glycol monomethyl ether, diethylene glycol dimethyl ether, 1,3-butanediol, 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane, 2-pyrrolidone, and N-methylpyrrolidone have proven particularly suitable. Instead of the substances s alone it is of course also possible to take blends thereof.
The saturation solubilities of fentanyl, measured in different liquids suitable for use as tile microreservoirs, are shown in table 1.
Table 1: Saturation solubility of fentanyl in different liquids Microreservoir liquid Solubility [%
wlw]
1,3-Butanediol 10 Dipropylene glycol 18 Transcutol* 25 Diethylene glycol diethyl26 ether N-Methylpyrrolidone 26 * Diethylene glycol monoethyl ether Accordingly, the solubility of fentanyl in base form is higher by a factor of about ~s 20 - 50 in the liquids envisaged for the microreservoirs than in the polysiloxane polymer. This is more than sufficient to accommodate the required amount of active substance within a microreservoir matrix not exceeding 200,um in thickness, in a system with an acceptable areal size.
2o The high solubility of fentanyl in the liquids envisaged for the microreservoirs coupled with its low solubility in the silicone polymer has the effect, moreover, that by far the predominant portion of the fentanyl is actually located within the microreservoirs and not in solution in the polymer phase.
Prior to application of a TTS of the invention, preferably more than 50% of the total active substance present in the TTS is situated within the microreservoirs, since otherwise, because of the poor solubility in the polymer, the active substance layers are too thick and the service properties poor for the finished system.
The total concentration of the active substance in the active substance layer is only between 2 and 5% by weight, which then also corresponds approximately to ~o the saturation concentration of the active substance in the polymer. This means that, despite the low concentration, the thermodynamic activity of the active substance is at a maximum, i.e., at or just below 1.
The fraction of the microreservoirs in the active substance layer may amount to up ~s to 40% by weight, although it is advantageous not to exceed 30% by weight.
It has proven advantageous to add to these liquids a substance which raises their viscosity. Such substances may comprise polymers which are capable of forming a gel with the liquid. Mention may be made by way of example of ethylcellulose 2o and hydroxypropylcellulose, which are also used in the examples. This measure facilitates the dispersibility of the liquid in the solution of the polymer and may also result in smaller microreservoir diameters.
For microreservoir systems of the invention which are provided with a membrane, 25 either microporous membranes or what are known as distribution membranes may be used. Microporous membranes are films provided with microscopic pores or channels. Here, the transport of active substance is substantially through these pores or channels, which must therefore be filled with a medium which is diffusible for the active substance (e.g., a liquid, gas, gel or other material). The number, the 3o internal surface area, and the size of the pores, and the physicochemical properties of the pore or channel filling substantially determine the release of active substance (permeation rate).
Distribution membranes do not possess any pores; in other words, the active substance must diffuse through the membrane material itself. When membranes of this kind are used, it is the thickness of the membrane, and the solubility and diffusion coefficient of the active substance in the membrane material, which determine the release of active substance. Distribution membranes which have proven particularly highly suitable are those based on copolymers of ethylene and vinyC acetate (EVA). Membranes of this kind are available in a variety of thicknesses and with different compositions. Customary thicknesses range ~o between 20 and 150 Nm, and the vinyl acetate (VA) content between 2 and 25%
by weight.
Since the VA content has an effect on the solubility and the diffusion coefficient of the active substances in the EVA polymers, it is a further important membrane ~ s characterization parameter where membranes made of this material are being used. In the examples, a membrane 50,um thick with a VA content of 9% by weight has been used. The permeation rates achieved using this membrane can be raised through the use of thinner membranes or membranes having a higher VA content. Naturally, the use of thicker membranes and the reduction of the VA
2o content has the opposite effect.
Especially when systems without membrane control are used, the active substance intake, i.e., the amount of active substance delivered by the TTS
that is actually absorbed via the skin into the blood circulation is also dependent on the 2s permeability of the skin. The outer skin layer in particular, the stratum corneum, forms the principal barrier against penetrative active substances. This barrier function can be lowered through the use of what are called enhancers, thereby increasing the active substance intake. Enhancers are known to the skilled worker, for example, from the publication "Skin penetration enhancers cited in the 3o technical literature" by David W. Osborne and Jill J. Henke, ViroTex Corporation, which can be called up on the Internet at http:/Iwww.pharmtech.com/technical/osborne/osborne.htm and which in order to avoid repetition is intended in its entirety to form part of the disclosure content of this specification.
For the transdermal therapeutic systems of the present invention it is possible with s particular advantage to use fatty acid, fatty acid ester, fatty alcohol or glycerol ester enhancers, especially when fentanyl is the active substance being used.
For fhe preparation of the active substance layer, the active substance is dissolved in the liquid which forms the microreservoirs, and this solution is dispersed in the solution of the polymer. The resulting dispersion is then used to coat an appropriate substrate - normally a polyester film with an abhesive coating - and the solvent of the polymer is removed by drying. The drying conditions should be chosen such that only a small proportion if any of the microreservoir solvent is removed. It has been found that the liquid and the solvent are preferably selected such that the solvent possesses a boiling temperature which is at least about 30°, with particular preference at least 50°, below the boiling temperature of the liquid.
The dry matrix film is then laminated to the backing layer of the system -usually 2o an active substance impermeable film with a thickness of about 15 - 30,um -and the individual transdermal therapeutic systems are then punched from the overall laminate obtained.
The production of corresponding microreservoir systems comprising membranes 2s is somewhat more complicated, but in terms of the coating and laminating process is no different from the production of known systems with the same layer sequence. In the examples, the production of microreservoir systems with and without membranes is described in detail.
3o Using three transdermal therapeutic systems provided by this invention, i.e.
microreservoir systems with and without membranes, permeation studies were conducted using human epidermis and Franz diffusion cells, which are known to the skilled worker. The composition and the results are summarized in tables 2 to 5, with the preparation process described in detail in the examples.
Table 2: Composition of the microreservoir systems without membranes Composition [% w/w]
Formulation A B C
Ingredients Fentanyl base 2.0 3.6 5.0 BIO-PSA 4301 * 80.0 80.0 80 1,3-Butanediol 17.46 Dipropylene glycol 16.07 Transcutol** 14.4 Hydroxypropyl-cellulose0.54 0.33 Ethylcellulose 100NF 0,6 Coating weight [glm']130 85 65 Matrix thickness, 140 95 75 approx. [arm]
* Amine-resistant silicone adhesive with high bond strength ** Diethylene glycol monoethyl ether Table 3: Results of the permeation study with formulations A, B and C
Cumulative Average permeated release fentanyl rate base [,ug/cm'J*
Formulation4 h 8 h 24 h 48 h 72 h [,ug/cm'*h]
D [sic] 1.2 9.5 84.4 194.0 275.0 3.82 E [sic] 1.12 8.87 75.80 191.00 283.00 3.93 F [sic] 16.20 45.20 131.00 212.00 262.00 3.64 * Averages of n = 3 Table 4: Composition of the systems with control membrane Composition [% w/w]
Formulation D E F
Ingredients Reservoir layer Fentanyl base 2.0 3.6 5.0 B I O-PSA 4301 * 80.0 80.0 80 1,3-Butanediol 17.46 Dipropylene glycol 16.07 Transcutol** 14.4 Hydroxypropyl-cellulose0.54 0.33 Ethylcellulose 100NF 0.6 Coating weight [glm']130 85 65 Control membrane EVA membrane 50,um, 9% VA
Skin contact layer BIO-PSA 4301 * 100 100 100 Coating weight [g/m']35 35 35 * Amine-resistant silicone adhesive with high bond strength ** Diethylene glycol monoethyl ether s Table 5: Results of the permeation study with formulations D, E and F
Cumulative Average permeated release fentanyl rate base [/rg/cm']*
Formulation4 h 8 h 24 h 48 h 72 h [~.~g/cm'*h]
D 1.4 4.9 26.2 64.0 99.8 1.39 E 2.7 8.1 37.0 85.0 129.0 1.79 F 0.8 4.7 45.3 114.0 166.0 2.31 * Averages of n = 3 Comparing the permeation results of the microreservoir systems with and without a membrane it can be seen that the amount of active substance permeated after 72 hours is much lower in the case of the membrane systems, despite the active substance layers having the same composition. This can be attributed to the controlling effect of the membrane, which limits the delivery of active substance to a maximum irrespective of the particular nature of the skin.
The graphs (figs. 3 and 4) also reveal that, as the result of the use of a membrane, the permeation profile is more linear and hence also the active substance intake in vivo is more uniform over the period of use. It is particularly evident in the case of formulation C, which shows the highest permeation rate.
The TTS present on the market (Durogesic~) is available in 4 strengths with average delivery rates of 25, 50, 75, and 100,um/hour. With these figures and the results of the permeation studies, it is possible to calculate the surface areas of the systems with ease. The results are summarized in table 6.
Table 6: Cahulated system surface areas of formulations A-F
Calculated Delivery areal rate sizes [cm ]
A B C D E F
,um/ 6.5 6.4 6.9 18.0 14.0 11.8 h 50 Nml 13.0 12.8 13.8 36.0 28.0 23.6 h 75 Nml 19.5 19.2 20.7 54.0 42.0 35.4 h 100 Nml 26.0 25.6 27.6 72.0 56.0 47.2 h 2o The calculated surface areas all lie within an acceptable range. The size of the microreservoir systems with membrane can be made smaller still through the use of thinner membranes or membranes with a higher VA content, although in that case the control of the delivery of active substance by the membrane will be less effective.
Microreservoir systems as provided by this invention therefore show very good permeation rates, which without a control membrane lead to TTS which are small in terms of area and are pleasant to wear. At the same time, there is absolutely no possibility of any risk to the patient from excessive active substance intake due to leakage.
s In the case of microreservoir systems with membranes, the membrane control which limits the delivery of active substance results in patch sizes which are larger but still acceptable.
All in all, therefore, microreservoir systems for fentanyl and the fentanyl analog 1 o derivatives constitute a decisive step forward in terms of wear comfort and patient safety from the known prior art.
The preparation examples which follow describe the preparation of microreservoir systems with and without membranes.
Example 1: Microreservoir system with 1,3-butanediol as liquid, formulation A
1 g of fentanyl base is dissolved in 9 g of 1,3-butanediol, thickened with 3%
hydroxypropylcellulose. To this solution there are added 54.8 g of a 73%
strength 2o solution of an amine-resistant silicone adhesive in n-heptane (BIO-PSA
4301, Dow Corning) and the active substance solution is dispersed in the solution of the silicone adhesive by rapid stirring. The dispersion is then knife-coated onto an abhesively coated film, the protective layer to be removed later prior to use (Scotchpak 1022, 3M), in a thickness which following removal of the n-heptane by drying at 30°C for 15 minutes results in a coating weight of 135 g/m2.
The dry film is then laminated with the active substance impermeable backing layer (Scotchpak 1220, 3M) and the finished transdermal therapeutic system is punched from the overall laminate which results.
Example 2: Microreservoir system with dipropylene glycol as liquid, formulation B
1 g of fentanyl base is dissolved in 4.6 g of dipropylene glycol, thickened with 2%
hydroxypropylcellulose. To this solution there are added 30.5 g of a 73%
strength s solution of an amine-resistant silicone adhesive in n-heptane (B!O-PSA 4301, Dow Corning) and the active substance solution is dispersed in the solution of the silicone adhesive by rapid stirring. The dispersion is then knife-coated onto an abhcsively coated film, the protective layer to be removed later prior to use (Scotchpak 1022, 3M), in a thickness which following removal of the n-heptane by drying at 30°C for 15 minutes results in a coating weight of 85 g/m2.
The dry film is then laminated with the active substance impermeable backing layer (Scotchpak 1220, 3M) and the finished transdermal therapeutic system is punched from the overall laminate which results.
~s Example 3: Microreservoir system with Transcutol as liquid, formulation C
1 g of fentanyl base is dissolved in 3 g of Transcutol, thickened with 4%
ethylcellulose. To this solution there are added 22 g of a 73% strength solution of an amine-resistant silicone adhesive in n-heptane (BIO-PSA 4301, Dow Corning) 2o and the active substance solution is dispersed in the solution of the silicone adhesive by rapid stirring. The dispersion is then knife-coated onto an abhesively coated film, the protective layer to be removed later prior to use (Scotchpak 1022, 3M), in a thickness which following removal of the n-heptane by drying at 30°C for 15 minutes results in a coating weight of 65 g/m2. The dry film is then laminated 2s with the active substance impermeable backing layer (Scotchpak 1220, 3M) and the finished transdermal therapeutic system is punched from the overall laminate which results.
Examples 4 - 6: Microreservoir systems with membranes, formulations D, E, and F
The solution of an amine-resistant silicone adhesive (BIO-PSA 4301, Dow s Corning) is knife-coated to an abhesively coated film (Scotchpak 1022, 3M) in a thickness such that removal of the n-heptane by drying at 30°C for 15 minutes gives a coating weight of 20 g/m2. The dried film is laminated with a membrane (EVA, 50Nm, 9% VA, 3M).
The protective layer is removed from the laminates from examples 1 - 3 and the laminate consisting of active substance layer and backing layer is laminated onto this membrane. The resulting overall laminate (formulations D, E and F) are then punched to give the finished transdermal therapeutic systems.
15 In the figures, the elements shown are as follows:
1 = backing layer 2 = active substance layer with microreservoirs 3 = microreservoir 4 = control membrane 20 5 = skin contact layer 6 = removable protective layer
Claims (15)
1. A transdermal therapeutic system (TTS) having increased security with regard to accidental administration of an overdose of the active substance comprising an active substance impermeable backing layer, an active substance layer, the active substance being fentanyl and/or a fentanyl analog derivative and/or a salt of fentanyl and/or a salt of a fentanyl analog derivative, where said active substance layer comprises a polymer or a polymer mixture with microreservoirs dispersed therein, a membrane layer following on the skin side, composed of an ethylene-vinyl acetate copolymer or of a microporous film based on polyethylene or polypropylene, where appropriate a subsequent adhesive layer, and finally a protective layer, which needs to be removed before use.
2. The TTS of claim 1, wherein the membrane layer is composed of an ethylene-vinyl acetate copolymer having a vinyl acetate content of from 2 to 25% by weight and a thickness of between 20 and 150 µm.
3. The TTS of claim 1 or 2, wherein the fraction of the microreservoirs in the active substance layer is up to 40% by weight.
4. The TTS of one or more of the preceding claims, wherein, where the membrane layer does not possess adhesive properties, an adhesive layer is located between membrane layer and protective layer.
5. The TTS of one or more of the preceding claims, wherein the polymer or polymer mixture is selected from the group consisting of polyisobutylenes and silicones.
6. The TTS of one or more of the preceding claims, wherein the polymer is an amine-resistant polysiloxane.
7. The TTS of one or more of the preceding claims, wherein the microreservoirs contain a liquid.
8. The TTS of any of the preceding claims, wherein the active substance is present completely dissolved in the microreservoirs.
9. The TTS of one or more of the preceding claims, wherein at least 50% of the active substance in the TTS is contained within the microreservoirs.
10. The TTS of one or more of the preceding claims, wherein the liquid comprises dipropylene glycol, diethylene glycol monoethyl ether, diethylene glycol diethyl ether, diethylene glycol monomethyl ether, diethylene glycol dimethyl ether, 1,3-butanediol, 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane, 2-pyrrolidone or N-methylpyrrolidone or a combination thereof.
11. The TTS of one or more the preceding claims, wherein the liquid comprises an additive which increases the viscosity, preferably ethylcellulose or hydroxy-propylcellulose.
12. The TTS of one or more of the preceding claims, wherein the concentration of the active substance in the active substance layer is below 5% by weight, preferably below 4% by weight.
13. The TTS of one or more of the preceding claims, wherein the weight of the active substance layer per unit area is between 30 and 300 g/m2.
14. The TTS of one or more of the preceding claims, wherein the active substance layer further comprises a substance which enhances the rate of permeation through human skin.
15. The TTS of claim 16, wherein the substance belongs to the group consisting of fatty acids, fatty acid esters, fatty alcohols, and glycerol esters.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10141651.2 | 2001-08-24 | ||
| DE10141651A DE10141651B4 (en) | 2001-08-24 | 2001-08-24 | Transdermal Therapeutic System (TTS) with the active ingredient Fentanyl and process for its preparation |
| PCT/EP2002/007663 WO2003018071A1 (en) | 2001-08-24 | 2002-07-10 | Transdermal therapeutic system (tts) with fentanyl as active ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2457245A1 CA2457245A1 (en) | 2003-03-06 |
| CA2457245C true CA2457245C (en) | 2010-09-07 |
Family
ID=7696569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2457245A Expired - Lifetime CA2457245C (en) | 2001-08-24 | 2002-07-10 | Transdermal therapeutic system (tts) containing the active substance fentanyl |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7390500B2 (en) |
| EP (1) | EP1418951B1 (en) |
| JP (1) | JP4628673B2 (en) |
| KR (1) | KR100895188B1 (en) |
| CN (1) | CN100438859C (en) |
| AT (1) | ATE455541T1 (en) |
| AU (1) | AU2002321199B2 (en) |
| BR (1) | BRPI0212028B8 (en) |
| CA (1) | CA2457245C (en) |
| CY (1) | CY1109954T1 (en) |
| DE (2) | DE10141651B4 (en) |
| DK (1) | DK1418951T3 (en) |
| ES (1) | ES2339640T3 (en) |
| HK (1) | HK1069534A1 (en) |
| HU (1) | HU229942B1 (en) |
| IL (2) | IL160515A0 (en) |
| MX (1) | MXPA04001679A (en) |
| NZ (1) | NZ530795A (en) |
| PL (1) | PL204348B1 (en) |
| PT (1) | PT1418951E (en) |
| RU (1) | RU2311908C2 (en) |
| TW (1) | TW570815B (en) |
| WO (1) | WO2003018071A1 (en) |
| ZA (1) | ZA200400473B (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10141650C1 (en) * | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate |
| US20040086551A1 (en) | 2002-10-30 | 2004-05-06 | Miller Kenneth J. | Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl |
| PL378076A1 (en) * | 2003-02-07 | 2006-02-20 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system suitable for heat application for promoting the permeation of active substances, and the use thereof |
| KR101050672B1 (en) * | 2003-04-14 | 2011-07-19 | 에르테에스 로만 테라피-시스테메 아게 | Therapeutic bandages with polysiloxane substrates containing capsaicin |
| US20110086086A1 (en) * | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
| DE102006019293A1 (en) * | 2006-04-21 | 2007-10-25 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Transdermal therapeutic system, useful for pain treatment, comprises a carrier layer, an adhesive layer comprising a pressure sensitive copolymer with a content of fentanyl and analogs and a removable protection layer |
| GB0615429D0 (en) * | 2006-08-03 | 2006-09-13 | Chowdhury Dewan F H | Transdermal drug delivery with temporal control |
| DE102006054731B4 (en) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for administration of the active ingredient buprenorphine and use thereof in pain therapy |
| DE102006054732B4 (en) * | 2006-11-21 | 2010-12-30 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with ion-pair microreservoirs |
| DE102008016804B4 (en) * | 2008-04-02 | 2012-01-05 | Lts Lohmann Therapie-Systeme Ag | Self-destructive transdermal therapeutic system with improved functionality and efficacy as well as its use |
| US20100221313A1 (en) * | 2008-12-01 | 2010-09-02 | Innovative Pharmaceuticals, Llc | Transdermal reservoir patch |
| IN2012DN00845A (en) * | 2009-07-21 | 2015-06-26 | Mylan Inc | |
| US9822088B2 (en) | 2011-03-30 | 2017-11-21 | The United States Of America As Represented By The Administrator Of Nasa | Anisotropic copoly(imide oxetane) coatings and articles of manufacture, copoly(imide oxetane)s containing pendant fluorocarbon moieties, oligomers and processes therefor |
| DE102011080390B3 (en) * | 2011-08-03 | 2012-07-12 | Acino Ag | application aid |
| SG11201403162XA (en) | 2011-12-12 | 2014-10-30 | Lohmann Therapie Syst Lts | Transdermal delivery system comprising buprenorphine |
| TW201431570A (en) * | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | Multi-day patch for the transdermal administration of rotigotine |
| CN105377245B (en) | 2013-06-04 | 2018-07-17 | Lts勒曼治疗系统股份公司 | Transdermal delivery system |
| CA2916183C (en) | 2013-07-03 | 2022-03-29 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with electronic component |
| CN106456566B (en) | 2014-05-20 | 2020-06-16 | Lts勒曼治疗系统股份公司 | Transdermal delivery system containing rotigotine |
| CA2948221C (en) | 2014-05-20 | 2022-11-22 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
| CN106456567A (en) | 2014-05-20 | 2017-02-22 | Lts勒曼治疗系统股份公司 | Method for adjusting the release of active agent in a transdermal delivery system |
| US9962340B2 (en) | 2015-06-09 | 2018-05-08 | Life Tech Global, Llc | Device and method for the transdermal delivery of cannabidiol |
| US10272125B2 (en) * | 2015-09-14 | 2019-04-30 | Life Tech Global, Llc | Transdermal delivery of cannabidiol with other active moieties including cannabinoids |
| US9650338B1 (en) | 2016-07-29 | 2017-05-16 | VDM Biochemicals, Inc. | Opioid antagonist compounds and methods of making and using |
| DE102017107468B4 (en) * | 2017-04-06 | 2019-02-21 | Lts Lohmann Therapie-Systeme Ag | PROCESS FOR PREPARING AN IN PARTICULAR ORAL, ACTIVE LAMINATE AND ACTIVE LAMINATE, IN PARTICULAR ORAL ACTIVE LAMINATE |
| EP3612495B1 (en) | 2017-04-18 | 2022-07-13 | Breakthrough Technologies, LLC | Sulfur production |
| CA3074636A1 (en) * | 2017-09-04 | 2019-03-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an emulsifier |
| JP6912122B2 (en) * | 2019-02-28 | 2021-07-28 | 日本臓器製薬株式会社 | Transdermal drug |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5310559A (en) * | 1982-09-01 | 1994-05-10 | Hercon Laboratories Corporation | Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer |
| US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
| US4645502A (en) * | 1985-05-03 | 1987-02-24 | Alza Corporation | Transdermal delivery of highly ionized fat insoluble drugs |
| US6110488A (en) * | 1986-08-28 | 2000-08-29 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system, its use and production process |
| US4906463A (en) * | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
| US4822802A (en) * | 1987-02-24 | 1989-04-18 | Alza Corporation | Method of fentanly administration for postoperative pain relief |
| US4849224A (en) * | 1987-11-12 | 1989-07-18 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
| FR2623718B1 (en) * | 1987-11-27 | 1994-04-15 | Fabre Medicament Pierre | TRANSDERMAL THERAPEUTIC DEVICE AND ITS PREPARATION METHOD |
| US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| DE3905051A1 (en) * | 1989-02-18 | 1990-08-30 | Lohmann Therapie Syst Lts | THERAPEUTIC SYSTEM FOR DELAYED AND CONTROLLED TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE SUBSTANCES (I) |
| DE3910543A1 (en) * | 1989-04-01 | 1990-10-11 | Lohmann Therapie Syst Lts | TRANSDERMAL THERAPEUTIC SYSTEM WITH INCREASED ACTIVE FLUID AND METHOD FOR THE PRODUCTION THEREOF |
| SE8904296D0 (en) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | TRANSDERMAL SYSTEM |
| JP3202777B2 (en) * | 1992-01-24 | 2001-08-27 | リンテック株式会社 | Transdermal absorption enhancer and tape preparation |
| JP3489831B2 (en) * | 1993-04-20 | 2004-01-26 | ヘクサル・アクチエンゲゼルシャフト | Active ingredient patch |
| CN1094972A (en) * | 1993-05-21 | 1994-11-16 | 深圳广信生物工程公司 | Release-controlled skin-penetrating therapeutic system and preparation thereof and application |
| JP3240496B2 (en) * | 1993-09-30 | 2001-12-17 | タキロン株式会社 | Transdermal formulation |
| US5665378A (en) * | 1994-09-30 | 1997-09-09 | Davis; Roosevelt | Transdermal therapeutic formulation |
| JP4346696B2 (en) * | 1996-05-28 | 2009-10-21 | 久光製薬株式会社 | Transdermal therapeutic device |
| DE19728517C2 (en) * | 1997-07-04 | 1999-11-11 | Sanol Arznei Schwarz Gmbh | TTS for the administration of sex steroid hormones and process for its preparation |
| KR19980025307A (en) * | 1998-04-11 | 1998-07-06 | 조태임 | Percutaneous Absorption of Drugs with Analgesic Effect |
| US6312715B1 (en) * | 1998-05-01 | 2001-11-06 | 3M Innovative Properties Company | Adhesive microsphere drug delivery composition |
| JP4428899B2 (en) * | 1999-07-02 | 2010-03-10 | エルテーエス ローマン テラピー−ジステーメ アーゲー | A microreservoir system based on polysiloxane and an amphiphilic solvent. |
| DE19958554C2 (en) * | 1999-07-02 | 2002-06-13 | Lohmann Therapie Syst Lts | Microreservoir system based on polysiloxanes and ambiphilic solvents and their manufacture |
| US6893655B2 (en) * | 2001-10-09 | 2005-05-17 | 3M Innovative Properties Co. | Transdermal delivery devices |
-
2001
- 2001-08-24 DE DE10141651A patent/DE10141651B4/en not_active Expired - Lifetime
-
2002
- 2002-07-10 EP EP02754860A patent/EP1418951B1/en not_active Expired - Lifetime
- 2002-07-10 DE DE50214184T patent/DE50214184D1/en not_active Expired - Lifetime
- 2002-07-10 WO PCT/EP2002/007663 patent/WO2003018071A1/en active IP Right Grant
- 2002-07-10 DK DK02754860.1T patent/DK1418951T3/en active
- 2002-07-10 RU RU2004108849/15A patent/RU2311908C2/en active
- 2002-07-10 CN CNB02816427XA patent/CN100438859C/en not_active Expired - Lifetime
- 2002-07-10 AT AT02754860T patent/ATE455541T1/en active
- 2002-07-10 HU HU0401512A patent/HU229942B1/en unknown
- 2002-07-10 KR KR1020047002709A patent/KR100895188B1/en active IP Right Grant
- 2002-07-10 MX MXPA04001679A patent/MXPA04001679A/en active IP Right Grant
- 2002-07-10 PT PT02754860T patent/PT1418951E/en unknown
- 2002-07-10 PL PL366857A patent/PL204348B1/en unknown
- 2002-07-10 US US10/487,375 patent/US7390500B2/en not_active Expired - Lifetime
- 2002-07-10 CA CA2457245A patent/CA2457245C/en not_active Expired - Lifetime
- 2002-07-10 AU AU2002321199A patent/AU2002321199B2/en not_active Expired
- 2002-07-10 ES ES02754860T patent/ES2339640T3/en not_active Expired - Lifetime
- 2002-07-10 IL IL16051502A patent/IL160515A0/en unknown
- 2002-07-10 JP JP2003522586A patent/JP4628673B2/en not_active Expired - Lifetime
- 2002-07-10 NZ NZ530795A patent/NZ530795A/en not_active IP Right Cessation
- 2002-07-10 BR BRPI0212028 patent/BRPI0212028B8/en not_active IP Right Cessation
- 2002-08-22 TW TW091119026A patent/TW570815B/en not_active IP Right Cessation
-
2004
- 2004-01-22 ZA ZA200400473A patent/ZA200400473B/en unknown
- 2004-02-23 IL IL160515A patent/IL160515A/en active IP Right Grant
-
2005
- 2005-03-11 HK HK05102132.0A patent/HK1069534A1/xx not_active IP Right Cessation
-
2008
- 2008-05-07 US US12/116,303 patent/US20080274167A1/en not_active Abandoned
-
2010
- 2010-03-29 CY CY20101100289T patent/CY1109954T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2457245C (en) | Transdermal therapeutic system (tts) containing the active substance fentanyl | |
| US10709669B2 (en) | Microreservoir system based on polysiloxanes and ambiphilic solvents | |
| AU639015B2 (en) | Method and device for administering dexmedetomidine transdermally | |
| KR100483476B1 (en) | A dual adhesive transdermal drug delivery system | |
| CA2726136C (en) | Stabilized transdermal drug delivery system | |
| AU2003289710B2 (en) | Therapeutic patch with polysiloxane matrix comprising capsaicin | |
| JPH0575727B2 (en) | ||
| JP3523259B2 (en) | Plasters containing volatile active substances that can be produced without solvents | |
| KR100685553B1 (en) | Microreservoir system on the basis of polysiloxanes and ambiphilic solvents | |
| KR100624500B1 (en) | Transdermal therapeutic system for the delivery of lerisetron | |
| EP2671573B1 (en) | Patch and patch preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20220711 |